Highly Variable Drug BE Justification [Regulatives / Guidelines]

posted by jag009  – NJ, 2017-03-20 04:42  – Posting: # 17166
Views: 19,105

(edited by jag009 on 2017-03-20 05:22)

Hi all,

Just want to know what your experience is on this matter.

The FDA stated that "Special Considerations: Applicants may consider using a reference-scaled average bioequivalence approach for x drug. If using this approach, the applicant should provide evidence of high variability (i.e., within-subject variability ≥30%) in bioequivalence parameters. Applicants who would like to use this approach are encouraged to submit a protocol for review by the Division of Bioequivalence in the Office of Generic Drugs."

The above implies that one can conduct replicate studies (RSABE) if he/she has supportive data (ISCV>=30%). What if one conducted pilot studies and found that the ISCV is like 28/29%? My concensus still would be to proceed with RSABE approach since the it is a mixed approach which allows both RSABE (if Ref SD<0.294) and ABE analysis (if Ref SD>0.294)

John

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,302 posts in 4,102 threads, 1,316 registered users;
online 9 (1 registered, 8 guests [including 7 identified bots]).

Restlessness is discontent –
and discontent is the first necessity of progress.
Show me a thoroughly satisfied man –
and I will show you a failure.    Thomas Alva Edison

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5